['Intensity-modulated arc therapy (IMAT) is attractive because of high-dose conformality and efficient delivery. However, managing intrafraction motion is challenging for IMAT. The purpose of this research was to develop and investigate electromagnetically guided dynamic multileaf collimator (DMLC) tracking as an enabling technology to treat moving targets during IMAT.', 'A real-time three-dimensional DMLC-based target tracking system was developed and integrated with a linear accelerator. The DMLC tracking software inputs a real-time electromagnetically measured target position and the IMAT plan, and dynamically creates new leaf positions directed at the moving target. Low- and high-modulation IMAT plans were created for lung and prostate cancer cases. The IMAT plans were delivered to a three-axis motion platform programmed with measured patient motion. Dosimetric measurements were acquired by placing an ion chamber array on the moving platform. Measurements were acquired with tracking, without tracking (current clinical practice), and with the phantom in a static position (reference). Analysis of dose distribution differences from the static reference used a γ-test.', 'On average, 1.6% of dose points for the lung plans and 1.2% of points for the prostate plans failed the 3-mm/3% γ-test with tracking; without tracking, 34% and 14% (respectively) of points failed the γ-test. The delivery time was the same with and without tracking.'] Does electromagnetic-guided dynamic multileaf collimator tracking enable motion management for intensity-modulated arc therapy?